Lipopolysaccharides: from Erinyes to Charites.
Following the discovery of endotoxins by Richard Pfeiffer, such bacterial product was associated to many severe disorders produced by an overwhelming inflammatory response and often resulting in endotoxic shock and multiple organ failure. However, recent clinical and basic sciences investigations claimed some beneficial roles of typical as well as atypical endotoxins. The aim of this paper is to focus on recent data supporting a beneficial activity of both typical and atypical endotoxins. Such novel perspective looks promising for development of new drugs for prevention and therapy of several human diseases.
Department of Health Sciences, Institute of Microbiology, University "Magna Graecia" of Catanzaro, Via T. Campanella 115, 88100 Catanzaro, Italy.
Alfredo
A
Focà
Maria Carla
MC
Liberto
Angela
A
Quirino
Giovanni
G
Matera
D000276:Adjuvants, Immunologic; D004731:Endotoxins / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D008070:Lipopolysaccharides / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity*; D014612:Vaccines / Q000737:chemistry / Q000276:immunology
D000276:Adjuvants, Immunologic; D004731:Endotoxins; D008070:Lipopolysaccharides; D014612:Vaccines